Skip to main content
Assets
Abbott Laboratories logo
ABT.NYSE
Abbott Laboratories
Health Care · Health Care Equipment

Global healthcare company developing medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals.

HQ: United StatesListed: United States

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for Abbott Laboratories.

Historical AI Forecasts

Abbott Laboratories (ABT.NYSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 28 November 2025Deep analysis 28 November 2025

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts

AI Advisor 1 AI

Independent Investor FrameworkAI Researcher

Model rating

Buy

5-Year Return Est.

+84.5%

Includes 1.69% annual net dividend contribution

1. Investment Thesis — Base Case

Abbott is projected to deliver consistent, defensive growth underpinned by its diversified business model. The successful European rollout of Volt PFA (CE Mark 2025) serves as a prelude to a robust US launch in 2026, offsetting maturity in legacy diagnostics. The FreeStyle Libre franchise continues to grow double-digits as it expands into the 'biowearable' consumer market, proving complementary to weight-loss drugs. While NEC litigation remains a headline risk, the mixed verdict history suggests a manageable eventual resolution rather than a catastrophic financial event. Financial performance is expected to show high-single-digit revenue growth and double-digit expansion, supporting a valuation re-rating to historical averages (~24-25x P/E) as the 'post-COVID' normalization fully resolves.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.70.68110.89151.11191.33231.55Nov 2020May 2023Nov 2025May 2028Nov 2030Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (USD)
Observed price2020-11-25108
Observed price2020-12-08107
Observed price2020-12-22108
Observed price2020-12-26108
Observed price2021-01-21113
Observed price2021-01-25114
Observed price2021-02-12128
Observed price2021-02-25120
Observed price2021-03-10117
Observed price2021-03-31119
Observed price2021-04-13123
Observed price2021-04-26122
Observed price2021-05-18117
Observed price2021-05-27116
Observed price2021-06-04109
Observed price2021-06-26114
Observed price2021-07-22120
Observed price2021-07-26121
Observed price2021-08-21125
Observed price2021-09-03129
Observed price2021-09-21125
Observed price2021-10-04116
Observed price2021-10-21125
Observed price2021-11-16130
Observed price2021-11-20126
Observed price2021-11-25125
Observed price2021-12-16136
Observed price2021-12-29141
Observed price2022-01-20126
Observed price2022-02-02130
Observed price2022-02-19120
Observed price2022-03-13117
Observed price2022-03-17122
Observed price2022-03-30118
Observed price2022-04-08123
Observed price2022-04-25117
Observed price2022-05-08108
Observed price2022-06-03116
Observed price2022-06-16103
Observed price2022-06-25107
Observed price2022-07-04110
Observed price2022-08-12111
Observed price2022-08-20108
Observed price2022-08-29102
Observed price2022-09-11107
Observed price2022-10-16104
Observed price2022-10-2096.2
Observed price2022-11-0296.7
Observed price2022-11-11104
Observed price2022-12-03106
Observed price2022-12-11110
Observed price2022-12-24108
Observed price2023-01-11114
Observed price2023-01-24112
Observed price2023-02-19105
Observed price2023-03-04103
Observed price2023-03-1298.3
Observed price2023-03-2598.2
Observed price2023-04-20110
Observed price2023-05-03112
Observed price2023-05-21107
Observed price2023-06-11101
Observed price2023-06-20106
Observed price2023-07-07107
Observed price2023-07-20114
Observed price2023-07-25114
Observed price2023-08-20104
Observed price2023-08-28104
Observed price2023-09-19100
Observed price2023-09-2398.1
Observed price2023-10-1592.2
Observed price2023-10-2893.5
Observed price2023-11-19101
Observed price2023-11-27102
Observed price2023-12-15109
Observed price2023-12-23109
Observed price2024-01-10114
Observed price2024-01-31113
Observed price2024-02-18116
Observed price2024-03-10120
Observed price2024-03-19112
Observed price2024-04-10112
Observed price2024-04-18106
Observed price2024-04-23107
Observed price2024-05-19104
Observed price2024-05-27102
Observed price2024-06-09106
Observed price2024-06-22105
Observed price2024-07-18101
Observed price2024-07-23104
Observed price2024-08-18111
Observed price2024-08-22112
Observed price2024-09-13117
Observed price2024-09-26113
Observed price2024-10-18117
Observed price2024-10-26115
Observed price2024-11-04117
Observed price2024-11-26119
Observed price2024-12-17113
Observed price2024-12-30113
Observed price2025-01-08114
Observed price2025-01-21121
Observed price2025-02-16132
Observed price2025-03-05137
Observed price2025-03-18127
Observed price2025-03-31132
Observed price2025-04-09125
Observed price2025-04-22130
Observed price2025-05-18135
Observed price2025-05-22132
Observed price2025-06-13135
Observed price2025-06-26137
Observed price2025-07-18122
Observed price2025-07-22126
Observed price2025-08-17132
Observed price2025-08-26132
Observed price2025-09-16134
Observed price2025-09-21135
Observed price2025-10-17129
Observed price2025-11-03124
Observed price2025-11-16130
Observed price2025-11-25128
Observed price2025-12-08123
Observed price2026-01-07127
Observed price2026-01-16123
Observed price2026-01-20121
Observed price2026-01-29106
Observed price2026-02-24114
Observed price2026-03-13108
Observed price2026-03-22105
Observed price2026-04-1796.5
Observed price2026-04-2592.6
Observed price2026-05-1384.1
Observed price2026-05-2685.9
Observed price2026-06-0891.2
Observed price2026-06-2190.0
Observed price2026-07-17101
Observed price2026-07-21100
Observed price2026-08-12111
Observed price2026-08-21117
Observed price2026-09-15102
Observed price2026-09-17102
Observed price2026-09-18103
Published advisor forecast2025-11-26129
Published advisor forecast2026-05-27143
Published advisor forecast2026-11-27151
Published advisor forecast2027-05-27161
Published advisor forecast2027-11-27169
Published advisor forecast2028-05-27178
Published advisor forecast2028-11-27187
Published advisor forecast2029-05-27194
Published advisor forecast2029-11-27203
Published advisor forecast2030-05-27210
Published advisor forecast2030-11-27218

2. Scenarios & Signals

Bull case

In this scenario, Abbott enters a 'MedTech Renaissance' driven by the successful US launch of the Volt Pulsed Field Ablation (PFA) system in 2026, which rapidly captures in the electrophysiology space. The FreeStyle Libre platform achieves ubiquitous adoption among Type 2 non-insulin users and pre-diabetics, positioning it as a premier wellness tool alongside therapies rather than a victim of them. Litigation risks related to NEC formula claims dissipate significantly following a string of courtroom victories similar to the October 2024 ruling, effectively capping liability exposure. Macroeconomic tailwinds, including a weaker dollar and lower interest rates, boost international earnings (EPD) and valuation multiples, driving the P/E ratio toward 28-30x as accelerates to the mid-teens.

Bear case

The bear case assumes a resurgence of legal headwinds where the July 2024 adverse verdict in the NEC formula litigation becomes a trend, forcing Abbott into a multibillion-dollar structured settlement that weighs on and dividends for years. Concurrently, long-term data on agonists begins to show a tangible reduction in cardiovascular events and diabetes progression, leading to slowing volume growth for structural heart devices and CGMs. Pricing pressure in China (Volume-Based Procurement) intensifies across diagnostics and pharmaceuticals, eroding margins. Market sentiment sours, compressing the to ~18x as investors view the company as a low-growth legacy conglomerate rather than a high-growth innovator.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus